表紙
市場調査レポート

下肢静止不能症候群 : パイプライン分析

Restless Legs Syndrome - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192807
出版日 ページ情報 英文 44 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
下肢静止不能症候群 : パイプライン分析 Restless Legs Syndrome - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 44 Pages
概要

下肢静止不能症候群(RLS、レストレスレッグス症候群)とは、別名ウィリス・エクボム病(WED)とも呼ばれる、神経系の一部の障害です。脚部に作用し、しきりに脚を動かしたくなるようになります。症状には痒みや疼痛、むず痒い感覚、ふくらはぎや脚部の痙攣などが含まれています。主な疾病素質としては、加齢などが想定されています。この疾患の治療薬には、筋弛緩剤や睡眠薬、麻酔薬などがあります。

当レポートでは、世界各国での下肢静止不能症候群(むずむず脚症候群)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

下肢静止不能症候群の概要

治療薬の開発

  • 下肢静止不能症候群向けパイプライン製品:概要
  • 下肢静止不能症候群向けパイプライン製品:比較分析

各企業で開発中の下肢静止不能症候群治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

下肢静止不能症候群治療薬:開発中の製品の一覧(企業別)

下肢静止不能症候群治療薬の開発に従事している企業

  • Alexza Pharmaceuticals, Inc.
  • Ascendis Pharma A/S
  • 久光製薬
  • Ligand Pharmaceuticals, Inc.
  • Mundipharma International Ltd
  • Omeros Corporation
  • Serina Therapeutics, Inc.
  • Vifor Pharma AG

下肢静止不能症候群:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (塩酸ナロキソン+塩酸オキシコドン)ER
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • フマル酸アプリンドル
  • AZ-008
  • カルボキシマルトース鉄(鉄欠乏性貧血治療)
  • OMS-527
  • 二塩酸塩プラミペキソール
  • 塩酸ロピニロール
  • SER-214

下肢静止不能症候群治療薬:最新の薬剤プロファイル

下肢静止不能症候群治療薬:開発が休止状態の製品

下肢静止不能症候群治療薬:開発が中止された製品

下肢静止不能症候群関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8248IDB

Summary

Global Markets Direct's, 'Restless Legs Syndrome - Pipeline Review, H2 2016', provides an overview of the Restless Legs Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome
  • The report reviews pipeline therapeutics for Restless Legs Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Restless Legs Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Restless Legs Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Restless Legs Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Restless Legs Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Restless Legs Syndrome Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Restless Legs Syndrome - Overview 7
  • Restless Legs Syndrome - Therapeutics under Development by Companies 8
  • Restless Legs Syndrome - Pipeline Products Glance 9
  • Late Stage Products 9
  • Clinical Stage Products 10
  • Early Stage Products 11
  • Restless Legs Syndrome - Products under Development by Companies 12
  • Restless Legs Syndrome - Companies Involved in Therapeutics Development 13
  • Alexza Pharmaceuticals, Inc. 13
  • Galenica Ltd. 14
  • Hisamitsu Pharmaceutical Co., Inc. 15
  • Ligand Pharmaceuticals, Inc. 16
  • Mundipharma International Ltd 17
  • Omeros Corporation 18
  • Restless Legs Syndrome - Therapeutics Assessment 19
  • Assessment by Monotherapy Products 19
  • Assessment by Combination Products 20
  • Assessment by Target 21
  • Assessment by Mechanism of Action 23
  • Assessment by Route of Administration 25
  • Assessment by Molecule Type 27
  • Drug Profiles 28
  • (naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • aplindore fumarate - Drug Profile 30
  • Product Description 30
  • Mechanism Of Action 30
  • R&D Progress 30
  • AZ-008 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • ferric carboxymaltose - Drug Profile 32
  • Product Description 32
  • Mechanism Of Action 32
  • R&D Progress 32
  • OMS-527 - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • ropinirole hydrochloride - Drug Profile 36
  • Product Description 36
  • Mechanism Of Action 36
  • R&D Progress 36
  • Restless Legs Syndrome - Dormant Projects 37
  • Restless Legs Syndrome - Discontinued Products 38
  • Restless Legs Syndrome - Product Development Milestones 39
  • Featured News & Press Releases 39
  • May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs 39
  • Jan 07, 2015: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome 40
  • Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome 41
  • Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome 41
  • Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease 42
  • Appendix 43
  • Methodology 43
  • Coverage 43
  • Secondary Research 43
  • Primary Research 43
  • Expert Panel Validation 43
  • Contact Us 43
  • Disclaimer 44

List of Tables

  • Number of Products under Development for Restless Legs Syndrome, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Late Stage Development, H2 2016 9
  • Comparative Analysis by Clinical Stage Development, H2 2016 10
  • Comparative Analysis by Early Stage Development, H2 2016 11
  • Products under Development by Companies, H2 2016 12
  • Restless Legs Syndrome - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016 13
  • Restless Legs Syndrome - Pipeline by Galenica Ltd., H2 2016 14
  • Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 15
  • Restless Legs Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 16
  • Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H2 2016 17
  • Restless Legs Syndrome - Pipeline by Omeros Corporation, H2 2016 18
  • Assessment by Monotherapy Products, H2 2016 19
  • Assessment by Combination Products, H2 2016 20
  • Number of Products by Stage and Target, H2 2016 22
  • Number of Products by Stage and Mechanism of Action, H2 2016 24
  • Number of Products by Stage and Route of Administration, H2 2016 26
  • Number of Products by Stage and Molecule Type, H2 2016 27
  • Restless Legs Syndrome - Dormant Projects, H2 2016 37
  • Restless Legs Syndrome - Discontinued Products, H2 2016 38

List of Figures

  • Number of Products under Development for Restless Legs Syndrome, H2 2016 7
  • Number of Products under Development by Companies, H2 2016 8
  • Comparative Analysis by Late Stage Development, H2 2016 9
  • Comparative Analysis by Early Stage Products, H2 2016 11
  • Assessment by Monotherapy Products, H2 2016 19
  • Number of Products by Targets, H2 2016 21
  • Number of Products by Stage and Targets, H2 2016 21
  • Number of Products by Mechanism of Actions, H2 2016 23
  • Number of Products by Stage and Mechanism of Actions, H2 2016 23
  • Number of Products by Routes of Administration, H2 2016 25
  • Number of Products by Stage and Routes of Administration, H2 2016 25
  • Number of Products by Stage and Molecule Types, H2 2016 27
Back to Top